Quick-Med Granted Additional NIMBUS® Patent

Gainesville, Florida – March 3, 2009 – Quick-Med Technologies, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,473,474 to Quick-Med covering select uses of the NIMBUS® technology.

This patent stems from a provisional patent application filed with the USPTO in February 2004 by Quick-Med. The new patent, together with a previously issued patent and eleven additional pending patent applications plus foreign counterparts pending in Europe, Australia, Brazil, Canada, China, India, Japan, Mexico, and South Africa, provide broad coverage for NIMBUS, an innovative, next-generation antimicrobial technology.

What makes NIMBUS different from other antimicrobial technology are its permanent bond and its ability to be effective even in the presence of large amounts of body fluids which can “blind” other antimicrobials. The active agent is permanently bonded to the substrate, keeping the biocide from depletion while killing microbes (such as MRSA, VRE, and many others) that are present on the substrate and maintaining continuing antimicrobial performance,. Being bound to the substrate keeps the antimicrobial at full strength; test results show that even in 90% serum, NIMBUS continues to kill microbes outperforming other antimicrobials.

NIMBUS technology is well-suited for a wide range of healthcare and consumer applications. The Company’s target applications include wound dressings, catheters and sutures, medical textiles, apparel, bed linens, incontinence products, persistent skin sanitizers, and adhesives.

Quick-Med has already licensed its first product, NIMBUS gauze, to Derma Sciences, Inc., a leading provider of advanced wound care products. Derma Sciences will market the product after Quick-Med receives FDA clearance.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. For more information, see: www.quickmedtech.com.

For additional further information, please contact QMT:

J. Ladd Greeno, CEO
Tel. (888) 835.2211 Ext 102
Email: lgreeno@quickmedtech.com

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements involve risks and uncertainties, including launch and approval of the potential products described herein and the Company¹s results of operations. The Company is also subject to other risks as detailed from time-to-time in the Company¹s SEC filings.